The reiteration of an Equal-Weight rating and maintenance of a $22 price target by Stephens & Co. suggests a neutral outlook on Anika Therapeutics' stock in the short term. This indicates that the analyst sees the stock as fairly valued at its current level, with no immediate catalysts expected to significantly change its valuation. Therefore, the impact on the stock price is likely to be neutral in the short term.